Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
What Is the Estimated Market Growth Potential of the Cancer Stem Cells Market by 2029?
The cancer stem cells market size has grown rapidly in recent years. It will grow from $2.93 billion in 2024 to $3.24 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to growth in funding for stemness pathway research, proliferation of flow cytometry and cell sorting capabilities in academic centers, integration of cancer stem cell endpoints in preclinical oncology studies, emergence of niche and microenvironment investigations and publication surge in cancer stem cell biology and therapy resistance mechanisms.
The cancer stem cells market size is expected to see rapid growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing use of comprehensive genomic profiling and whole transcriptome analysis in hospitals, rising demand for minimal residual disease monitoring in solid and blood cancers, growth in circulating tumor cell and circulating tumor deoxyribonucleic acid testing adoption, scale-up of single-cell sequencing and proteomics in clinical research networks and increasing prevalence of therapy-resistant and relapsed cancer cases. Major trends in the forecast period include integration of single-cell multimaps combining genomics transcriptomics proteomics and epigenomics, artificial intelligence and machine learning assisted identification of rare tumor-initiating cells, microfluidics based gentle cell sorting and closed system sample handling, organoid and tumoroid co-culture models with immune and stromal components and spatial transcriptomics and spatial proteomics mapping of stemness niches.
Claim your free report sample now:
Which Key Growth Contributors Will Drive the Cancer Stem Cells Market in the Next Decade?
The rising demand for personalized medicine is expected to propel the growth of the cancer stem cells market going forward. Personalized medicine refer to treatment approaches that are designed based on the genetic makeup, tumor biology, and individual response patterns of each patient to achieve higher effectiveness and lower side effects. The demand for personalized medicine is increasing due to the availability of genomic sequencing technologies, which are becoming more affordable and widely used in oncology research and clinical care. Personalized medicine targets cancer stem cells (CSCs) by tailoring treatments to the specific molecular and genetic characteristics of a patient’s tumor. Tumors are first analyzed for mutations, signaling pathways, and surface markers unique to their CSC population, allowing clinicians to select therapies that inhibit critical pathways. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the rising demand for real-time risk assessment and mitigation solutions is driving the growth of the cancer stem cells market.
What Segments Are Covered in the Cancer Stem Cells Market Report?
The cancer stem cells market covered in this report is segmented
1) By Type: Solid Tumor Stem Cells, Hematopoietic Stem Cells, Breast Cancer Stem Cells, Colorectal Cancer Stem Cells, Brain Cancer Stem Cells, Leukemia Stem Cells
2) By Cancer Forms: Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver, Other Cancer Forms
3) By Mode Of Action: Targeted Cancerous Stem Cells (Cscs), Stem Cell-Based Cancer Therapy
4) By Research Type: Basic Research, Clinical Research, Preclinical Research, Translational Research
5) By End User: Pharmaceutical And Biotechnology Companies, Research And Academic Institutions, Hospitals And Laboratories, Contract Research Organizations (CROs)
Subsegments
1) By Solid Tumor Stem Cells: Lung Cancer Stem Cells, Liver Cancer Stem Cells, Pancreatic Cancer Stem Cells, Prostate Cancer Stem Cells, Ovarian Cancer Stem Cells
2) By Hematopoietic Stem Cells: Myeloid Stem Cells, Lymphoid Stem Cells, Erythroid Stem Cells, Megakaryocytic Stem Cells, Granulocytic Stem Cells
3) By Breast Cancer Stem Cells: Triple Negative Breast Cancer Stem Cells, Hormone Receptor Positive Breast Cancer Stem Cells, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Stem Cells, Metastatic Breast Cancer Stem Cells, Inflammatory Breast Cancer Stem Cells
4) By Colorectal Cancer Stem Cells: Adenocarcinoma Colorectal Cancer Stem Cells, Mucinous Colorectal Cancer Stem Cells, Signet Ring Cell Colorectal Cancer Stem Cells, Metastatic Colorectal Cancer Stem Cells, Serrated Colorectal Cancer Stem Cells
5) By Brain Cancer Stem Cells: Glioblastoma Stem Cells, Medulloblastoma Stem Cells, Astrocytoma Stem Cells, Oligodendroglioma Stem Cells, Ependymoma Stem Cells
6) By Leukemia Stem Cells: Acute Myeloid Leukemia Stem Cells, Chronic Myeloid Leukemia Stem Cells, Acute Lymphoblastic Leukemia Stem Cells, Chronic Lymphocytic Leukemia Stem Cells, Mixed Phenotype Acute Leukemia Stem Cells
Which Trends Are Expected to Redefine the Cancer Stem Cells Market Landscape?
Major companies operating in the cancer stem cells market are focusing on technological advancements such as pre-analytical immunomagnetic sorting systems to enhance cell enrichment for improved diagnostic accuracy. Pre-analytical immunomagnetic sorting systems refer to advanced tools that use magnetic particles coated with antibodies to isolate specific cancer stem cell populations from complex biological samples, improving sensitivity and reproducibility in downstream assays. For instance, in March 2024, STEMCELL Technologies, a Canada-based biotechnology company, launched the EasySep Human Bone Marrow CD138 Positive Selection Kit. The kit is the first hematopoietic cell enrichment product to receive FDA de novo classification as a Class II in vitro diagnostic device. It enriches CD138+ plasma cells from bone marrow samples to improve the detection of multiple myeloma-related abnormalities. The product ensures higher sensitivity, reproducibility, and diagnostic accuracy, ultimately improving patient outcomes in multiple myeloma care. The purpose of the product is to strengthen the pre-analytical stage of cancer diagnostics by delivering high-purity cell populations that allow more reliable downstream testing.
Who Are the Most Influential Players in the Cancer Stem Cells Market?
Major companies operating in the cancer stem cells market are MacroGenics Inc., Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Lonza Group AG, A. Menarini Industrie Farmaceutiche Riunite S.r.l., Bio-Techne Corporation, Zymeworks Inc., Kura Oncology Inc., GeneTex Inc., YZY Biopharma Co. Ltd., Abnova (Taiwan) Corporation, BioView Ltd., ScienCell Research Laboratories Inc., Boster Biological Technology Co. Ltd., BioFluidica Inc., AAT Bioquest Inc., Celprogen Inc., Actinium Pharmaceuticals Inc.
Get the full cancer stem cells market report here:
Which Region Is Projected to Account for the Largest Share of the Cancer Stem Cells Market?
North America was the largest region in the cancer stem cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer stem cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
Comments
Post a Comment